Table 1.
Treatments and number of animal used for each assay
| Assay | |||
|---|---|---|---|
| Pretreatment | Acute treatment | NAc | VTA |
| Placebo | Saline | DA and DOPAC levels, DOPAC/DA ratio (n = 6), THpSer31 (n = 7), THpSer40 (n = 8), tTH (n = 7) | Ago2 (n = 6), Nurr1 (n = 6), Pitx3 (n = 6), tTH (n = 6) |
| Placebo | Morphine (1 h) | DA and DOPAC levels, DOPAC/DA ratio (n = 4) | |
| Placebo | Morphine (2 h) | DA and DOPAC levels, DOPAC/DA ratio (n = 5), THpSer31 (n = 8), THpSer40 (n = 8), tTH (n = 7) | Ago2 (n = 8), Nurr1 (n = 7), Pitx3 (n = 7), tTH (n = 8) |
| Placebo | Saline | DOPAC/DA ratio (n = 8), THpSer31 (n = 6), THpSer40 (n = 8), tTH (n = 7) | Ago2 (n = 7), Nurr1 (n = 6), Pitx3 (n = 6), THpSer31 (n = 8), THpSer40 (n = 6), tTH (n = 8), Nurr1/tTH and Pitx3/tTH colocalization (IF) (n = 3) |
| Placebo | Naloxone | DOPAC/DA ratio (n = 5), THpSer31 (n = 6), THpSer40 (n = 7), tTH (n = 6) | Ago2 (n = 8), Nurr1 (n = 8), Pitx3 (n = 7), THpSer31 (n = 7), THpSer40 (n = 7), tTH (n = 8) |
| Morphine | Saline | DOPAC/DA ratio (n = 6), THpSer31 (n = 6), THpSer40 (n = 7), tTH (n = 7) | Ago2 (n = 8), Nurr1 (n = 8), Pitx3 (n = 7), THpSer31 (n = 8), THpSer40 (n = 7), tTH (n = 7), Nurr1/tTH and Pitx3/tTH colocalization (IF) (n = 3) |
| Morphine | Naloxone | DOPAC/DA ratio (n = 6), THpSer31 (n = 6), THpSer40 (n = 7), tTH (n = 6) | Ago2 (n = 8), Nurr1 (n = 8), Pitx3 (n = 6), THpSer31 (n = 7), THpSer40 (n = 7), tTH (n = 8), Nurr1/tTH and Pitx3/tTH colocalization (IF) (n = 3) |
DOPAC, 3,4-Dihydroxyphenylacetic acid.